Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERCK MEDICAID PROPOSAL ACCEPTED BY UTAH; DELAWARE, SOUTH CAROLINA MAY BE NEXT

Executive Summary

Utah's state Medicaid agency reportedly has accepted Merck's legislative proposal to obtain prescription drug price discounts in exchange for open access to Merck products. Arkansas, which like Utah has an open formulary, already has accepted Merck's proposal ("The Pink Sheet" May 7, p. 3). In addition, the company says that Delaware and South Carolina "seem certain" to accept the offer. Utah accepted the proposal under two conditions, which were agreed to by Merck. The state did not want to sign a contract that bound its Medicaid agency to keeping an open formulary for all Merck products in perpetuity. The state also wanted to maintain a prior approval constraint on Pepcid prescriptions; Utah was concerned that physicians may order therapeutic doses for patients who need only maintenance doses. Merck reportedly accepted the dosing constraint because it is not more restrictive than the FDA-approved label recommendation. Merck Sharp & Dohme President John Zabriskie told "The Pink Sheet" that although the company is "still in discussion" with most states," it is "hopeful that as many as 40 states" will accept the proposal by mid-summer. About 25 of those states currently have open formularies. Merck is particularly interested in having its offer accepted by those with restrictive formularies. About 13 states have formularies that are closed to Merck products, Zabriskie said. Another 12 restrict access to at least one Merck product -- for example, by requiring prior authorization. Of those 12, he added, at least six have indicated "strong interest" in the legislative proposal. Zabriskie contrasted Merck's proposal from the Medicaid bill sponsored by Sen. Pryor (D-Ark.). The Senate bill (S 2605) would "limit access" of Medicaid patients to prescription drugs, whereas the Merck proposal would "guarantee access." He maintained that, "socially and medically, government should be encouraging full access" to pharmaceuticals.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel